Avigen, Inc. Completes Multi-Center AV650 Phase 2b Spasticity Trial in Patients With Multiple Sclerosis

in

ALAMEDA, Calif., Sept. 18, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced the completion of the double-blind portion of its Phase 2b trial for AV650 (tolperisone HCl) in the treatment of spasticity associated with multiple sclerosis (MS). This Phase 2b spasticity trial is evaluating the safety, tolerability...